It reiterated that pilgrims require a Haj visa and it can be obtained through recognised official channels
Chinese vaccine firm CanSino Biologic's inhalation-based candidate elicited a better antibody response as a booster against the BA.1 Omicron sub-variant than Sinovac's shot, but the antibody level dropped in months, clinical trial data showed.
The result came as top political leaders in China called for proper tracking of virus mutation and developing of new vaccines and treatments in the country's effort to refine its Covid control strategy.
China has given about 56 per cent of its 1.41 billion population a booster dose using domestic shots, and most people were boosted with the same product as their primary series, despite growing evidence that some mix-and-max strategies would likely achieve higher antibody levels. read more
Among over 100 adults who received a lower dose of CanSinoBIO's (6185.HK) inhaled vaccine candidate following two Sinovac shots, after four weeks, 92.5 per cent developed the neutralising antibody that neutralises Omicron at levels that researchers defined as detectable, according to a paper published without peer review.
That compared with 88.9 per cent for a higher-dose group, also with over 100 participants, said in a paper published late on Thursday.
The rate for both groups declined to around 70 per cent after six months of the inhaled booster.
Barely any of the over 100 participants who received a third Sinovac shot had detectable neutralising antibody for Omicron after four weeks or six months.
The study did not compare CanSinoBIO's inhaled booster with other potential boosters that have triggered stronger antibody responses than a third dose of the Sinopharm or Sinovac shot.
Antibody-based readings reflect an important part of the vaccine-triggered immune response, and are different from the vaccine efficacy that indicates how well a shot reduces the risk of Covid disease, hospitalization or death.
The impact of BA.4 and BA.5 Omicron sub-variants on CanSinoBIO's inhaled vaccine deserves further study, said the authors, who worked at CanSinoBIO and other Chinese institutes.
CanSinoBIO's experimental inhaled vaccine uses a technology similar to that of its injection-based shot, which has been approved in countries including China, Mexico and Argentina, and AstraZeneca's vaccine.
The company is also testing a candidate based on the mRNA method in a mid-stage clinical trial in China.
ALSO READ:
It reiterated that pilgrims require a Haj visa and it can be obtained through recognised official channels
The 18-year-old was taken to hospital in a serious condition
The brothers, who say they are innocent, are accused of having formed an organised criminal network in early 2021 in Romania, as well as in the US and Britain
The left-handed batter scored 3369 runs in 136 one-day internationals and 2893 in 140 Twenty20 internationals — both Pakistan records
Food supplies were distributed to 80 households
On January 31, a heart was airlifted from Delhi to Chennai, paving the way for Ayesha Rashid's life-saving surgery
The online retailer, which is headquartered in Singapore, has said it has around 108 million monthly active users in the 27-nation EU
The baby girl named Rouh, meaning Soul, suffered respiratory problems and a weak immune system, a doctor at the Emirati Hospital in Rafah said